Could you do us a small favour? Please forward our digital booklet or website link to your friends, family and physicians who may know someone who wants to save money on their prescription drugs. A larger customer base grows our volume buying power, gives us priority access to medication inventories globally to assist with procurement and delivery timelines, and it reduces our cost of overhead per customer to help keep costs lower for everyone. We appreciate your support!
On behalf of the Campaign for Personal Prescription Importation (CPPI), I'm writing to say thank you. CPPI Members and other concerned citizens like you have submitted over 50,000 letters to Congress calling for an end to the Domain Reform for Unlawful Drug Sellers Act (the DRUGS Act). This incredible effort stalled the bill from advancing -- so far.
The DRUGS Act, which was introduced by Senator Marco Rubio (R-FL) late in 2021 and is backed by Big Pharma special interests, aims to cut off Americans’ access to licensed international online pharmacies that sell the same safe medications at a fraction of the Big Pharma U.S. prices.
"… Big Pharma will lead an effort to have the DRUGS Act reintroduced when the new Congress convenes in 2023."
The swell of letters from CPPI members and people like you calling for Congress to “Say No to the DRUGS Act'' successfully halted the momentum of the bill this year, and also had the effect of convincing Senator Amy Klobuchar (D-MN) to remove her support from the bill. With the defeat of Representative David McKinley (R-WV-1), the House bill also sits without bi-partisan sponsorship.
The Fight is Not Over
While we have seen tremendous success fighting the DRUGS Act in 2022, Big Pharma has increased their efforts to block American’s access to importation of affordable medications. There is every indication that Big Pharma will lead an effort to have the DRUGS Act reintroduced when the new Congress convenes in 2023.
We will tell you more about how you can help once we know more. In the meantime, one of CPPI’s leading advocacy tools to protect access to affordable prescription medications is the annual CPPI Survey that enables us to educate Congress on the impact that prescription importation has on American lives.